Production (Stage)
Addex Therapeutics Ltd
ADXN
$8.40
$0.192.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -74.36% | -71.75% | -58.86% | -14.54% | 20.27% |
| Total Other Revenue | 44.68% | -31.48% | -75.00% | -71.02% | -80.17% |
| Total Revenue | -74.03% | -71.54% | -58.97% | -15.09% | 18.69% |
| Cost of Revenue | -27.11% | -70.53% | -76.64% | -88.48% | -91.37% |
| Gross Profit | -206.84% | 68.82% | 87.90% | 101.95% | 103.38% |
| SG&A Expenses | -11.95% | -23.95% | -39.57% | -46.18% | -61.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.62% | -46.08% | -59.30% | -74.08% | -81.34% |
| Operating Income | -24.38% | 35.36% | 59.38% | 80.80% | 88.35% |
| Income Before Tax | -99.11% | 6.21% | 52.68% | 79.67% | 87.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -99.11% | 6.21% | 52.68% | 79.67% | 87.19% |
| Earnings from Discontinued Operations | 246.54% | 262.05% | 291.24% | -329.55% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 164.32% | 146.34% | 133.19% | 30.00% | 46.13% |
| EBIT | -24.38% | 35.36% | 59.38% | 80.80% | 88.35% |
| EBITDA | -16.35% | 38.34% | 60.31% | 80.62% | 88.24% |
| EPS Basic | 148.12% | 128.28% | 113.80% | 61.52% | 69.45% |
| Normalized Basic EPS | -54.59% | 40.38% | 72.34% | 89.31% | 92.98% |
| EPS Diluted | 143.73% | 124.97% | 113.21% | 60.49% | 68.67% |
| Normalized Diluted EPS | -36.24% | 47.73% | 76.29% | 89.31% | 92.98% |
| Average Basic Shares Outstanding | 32.13% | 42.11% | 50.87% | 63.78% | 64.87% |
| Average Diluted Shares Outstanding | 55.58% | 68.13% | 80.12% | 63.78% | 64.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |